The Beauty Health Company (SKIN)
NASDAQ: SKIN · Real-Time Price · USD
1.140
+0.010 (0.88%)
At close: Mar 6, 2026, 4:00 PM EST
1.150
+0.010 (0.88%)
After-hours: Mar 6, 2026, 7:50 PM EST
The Beauty Health Company Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for The Beauty Health Company stock have an average target of 2.00, with a low estimate of 1.25 and a high estimate of 3.50. The average target predicts an increase of 75.44% from the current stock price of 1.14.
Analyst Consensus: Buy
* Price targets were last updated on Jan 21, 2026.
Analyst Ratings
The average analyst rating for The Beauty Health Company stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold Maintains $1.5 → $1.65 | Hold | Maintains | $1.5 → $1.65 | +44.74% | Jan 21, 2026 |
| Jefferies | Jefferies | Hold Initiates $1.6 | Hold | Initiates | $1.6 | +40.35% | Jan 14, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $2 → $2.5 | Hold | Maintains | $2 → $2.5 | +119.30% | Sep 22, 2025 |
| Roth Capital | Roth Capital | Strong Buy Initiates $3.5 | Strong Buy | Initiates | $3.5 | +207.02% | Sep 19, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $1.5 → $1.25 | Hold | Maintains | $1.5 → $1.25 | +9.65% | May 5, 2025 |
Financial Forecast
Revenue This Year
302.52M
from 334.29M
Decreased by -9.50%
Revenue Next Year
315.90M
from 302.52M
Increased by 4.42%
EPS This Year
-0.06
from -0.36
EPS Next Year
-0.11
from -0.06
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 315.2M | 347.6M | ||
| Avg | 302.5M | 315.9M | ||
| Low | 288.6M | 292.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -5.7% | 14.9% | ||
| Avg | -9.5% | 4.4% | ||
| Low | -13.7% | -3.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.03 | 0.07 | ||
| Avg | -0.06 | -0.11 | ||
| Low | -0.09 | -0.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.